Commercial reagents were used as received without further purification. Commercial anhydrous solvents were used in reactions and HPLC grade solvents were employed for work-up and chromatography. NMR spectra were recorded using a Varian Mercury 300 MHz or 400 MHz for 1 H and 75 MHz or 101 MHz for 13 C. The solvent was used as internal deuterium lock. Coupling constants (J) are analytes was performed upon Centurysil C18-AQ+ 5μm, 50×4.6mm (Johnson). The flow rate of the mobile phase was kept at 3.5 mL/min. Mobile phases B and C were acetonitrile with 0.35% CF 3 CO 2 H and water with 0.35% CF 3 CO 2 H respectively. The gradient conditions were as follows: 0-0.5 min 1% B and 99% C, 3.7 min 90% B and 10% C, 5 min 99% B and 1% C. The injection volume was 10 μl. Compound purity was assessed at 254 nm and by evaporative light scattering detection (ELSD). 
6-(3,5-Dimethyl-isoxazol-4-yl)-indan-1-one (6)
1 M aqueous NaHCO 3 (15 mL, 15 mmol) was added to a mixture of 6-bromo-indan-1-one 5a (1.06 g, 5.00 mmol), 3,5-dimethylisoxazole-4-boronic acid pinacol ester (1.34 g, 6.00 mmol) and Pd(dppf)Cl 2 (73 mg, 0.10 mmol) in DME (25 mL). The mixture was degassed by evacuating and refilling with nitrogen several times then heated to 100 °C and left to stir at this temperature for 18 h. 25 The resulting purple mixture was allowed to cool then treated with activated charcoal. The mixture was filtered through a Celite ® plug then washed through with EtOAc. The resulting brown filtrate was concentrated in vacuo then partitioned between EtOAc (50 mL) and 10% aq. K 2 CO 3 solution (50 mL). The organic phase was washed with water (50 mL) and brine (50 mL) then MgSO 4 and more activated charcoal was added. The mixture was filtered then the resulting golden filtrate was evaporated to a cream solid. This was triturated with tert-butyl methyl ether (~15 mL) then filtered and dried under vacuum to yield the title product as a taupe solid (559 mg, 49% NaH (76.8 mg, 3.2 mmol) was added to a solution of (±)-6-(3,5-dimethylisoxazol-4-yl)-2,3-dihydro-1H-inden-1-ol (72 mg, 0.32 mmol) in THF (5 mL). The mixture was heated at reflux for 0.5 h. Benzyl bromide was added slowly to the reaction mixture at 60 °C. The reaction was allowed to stir at this temperature for 18 h then allowed to cool. Distilled water was added to the reaction mixture then this 20 was extracted with diethyl ether. The organic layers were combined, washed with brine, dried over anhydrous Na 2 SO 4 Phenylmangesium bromide (3.0 M in Et 2 O, 0.98 mL, 2.9 mmol) was added drop-wise to a cooled (ice bath) suspension of 6-(3,5-dimethyl-isoxazol-4-yl)-indan-1-one (6) (555 mg, 2.44 mmol) in THF (10 mL). The mixture was allowed to warm to room temperature slowly then left to stir for 16 h. More phenylmangesium bromide (3.0 M in Et 2 O, 0.407 mL, 1.22 mmol) was added at 0 °C then the mixture was allowed to warm to room temperature, left to stir for 3 h then more phenylmangesium bromide (3.0 M in Et 2 O, 0.40 mL, 1.2 15 mmol) was added. Saturated aq. NH 4 Cl solution (25 mL) was added then the mixture was stirred for 5 min, transferred to a separating funnel then extracted with EtOAc (3 × 25 mL). The combined organic phases were washed with water (25 mL) and brine (25 mL) then dried over Na 2 SO 4 and evaporated. The crude was purified by column chromatography, eluting with EtOAc:heptane and increasing the gradient linearly from 20:80 to 100:0 over 12 column volumes. The desired fractions were combined and evaporated to yield the title compound as a pale yellow gum ( 
4-(1H-Benzo[d]imidazol-6-yl)-3,5-dimethylisoxazole (8)

25
Et 3 N (3 mL, 20 mmol) was added to a solution of 5-bromobenzimidazole (2.0 g, 10 mmol) in CH 2 Cl 2 (110 mL). After stirring for 2 min, di-tert-butyl dicarbonate (4.4 g, 20 mmol) was added to the reaction mixture at 0 °C, then the reaction was stirred for 4 h at rt. The mixture of the reaction was washed with H 2 O and brine, dried over Na 2 SO 4 then concentrated in vacuo. The crude product was purified by silica gel column chromatography (petroleum ether:EtOAc 5:1) to yield a mixture of the regioisomers of the Boc-protected imidazole 30 as a yellow oil (4.4 g). This material was dissolved in dioxane (50 mL) then Pd(PPh 3 ) 4 (1.7 g, 1.5 mmol), 3,5-dimethylisoxazol-4-ylboronic acid (4.23 g, 30 mmol), and aqueous Na 2 CO 3 (2 M, 20 mL) were added. The reaction mixture was heated to reflux then stirred for 4 h. After cooling to rt, the mixture was concentrated in vacuo. The residue was diluted in EtOAc then washed with H 2 O and brine then dried over Na 2 SO 4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography (CH 2 Cl 2 :EtOAc 1:1) to yield the title compound as a yellow solid (1.48 g, 68 % 1-(4-Chlorobenzyl)-1H-benzo[d]imidazol-6-yl)-3,5-dimethylisoxazole (23a) and 4-(1-(4-chlorobenzyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (23b) Separation method K 2 CO 3 (129 mg, 0.93 mmol) was added to a solution of compound 8 (100 mg, 0.47 mmol) in CHCl 3 (5 mL) followed by dropwise 5 addition of 1-(bromomethyl)-4-chlorobenzene (116 mg, 0.56 mmol). The reaction mixture was heated under reflux and monitored by TLC. After completion, the reaction was allowed to cool to rt,then the mixture was filtered. The filtrate was diluted with CH 2 Cl 2 , washed with H 2 O and brine then dried over Na 2 SO 4 
4-(
4-(1-(4-Chlorobenzyl)-1H-benzo[d]imidazol-6-yl)-3,5-dimethylisoxazole (23a)
15 K 2 CO 3 (222 mg, 1.60 mmol) was added to a solution of 2,4-dibromo-1-nitrobenzene (300 mg, 1.07 mmol) and (4-chlorophenyl)methanamine (144 µL, 1.17 mmol) in DMSO. The mixture was stirred at 76 °C for 18 h. The reaction mixture was partitioned between EtOAc (30 mL) and water (10 mL). The organic phase was washed with saturated NaHCO 3 (×3), dried over Na 2 SO 4 then the solvent was removed under reduced pressure. 4 (18 mg, 10%) and K 2 CO 3 (53 mg, 0.38 mmol) in dioxane and water was stirred under Ar at 120 °C. The reaction was monitored by TLC. On completion the reaction mixture was allowed to cool then water was added. 
4-(1-(4-Chlorobenzyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (23b)
Na 2 CO 3 (75 mg, 0.71 mmol) was added to a solution of 1,4-dibromo-2-nitrobenzene (100 mg, 0.36 mmol) and chlorophenyl)methanamine (108 mg, 0.89 mmol) in EtOH. The mixture was stirred at 80 °C for 66 h. The reaction mixture was concentrated in vacuo then partitioned between EtOAc (30 mL) and water (10 mL). The organic phase was dried over Na 2 SO 4 then the solvent was removed under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether:EtOAc 50:1) to yield 4-bromo-N-(4-chlorobenzyl)-2-nitroaniline (110 mg, 90%). Iron powder (557 mg 9.94 mmol) was added to a suspension of 4-bromo-N-(4-chlorobenzyl)-2-nitroaniline (566 mg, 1.66 mmol) in EtOH:H 2 O (4:1, 10 mL). The reaction mixture was stirred at room 40 temperature for 0.5 h then ammonium chloride (89 mg, 1.66 mmol) was added. The resulting mixture was heated at 93 °C for 18 h then allowed to cool to room temperature. The reaction mixture was diluted with EtOAc then the insoluble material was filtered and washed with methanol. The filtrate was concentrated in vacuo then the residue was dissolved in EtOAc. The resulting solution was washed with water and brine then dried over Na 2 SO 4 and evaporated. The residue was purified by silica gel (petroleum ether:EtOAc 25:1 to 10:1) to yield 4-bromo-N1-(4-chlorobenzyl)benzene-1, 
4-(1-(4-Chlorobenzyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (28a)
15
The title compound was prepared in a manner analogous to compound 23a (separation method). 
X-ray Crystallography
Cloning, Protein Expression and Purification -cDNA encoding human BRD4 (NCBI accession numbers NP 055114.1) was obtained from FivePrime and was used as template to amplify the N-terminal bromodomain region of the protein. Protein expression and purification was carried out as previously described 1 .
25
Crystallization: Aliquots of the purified proteins were set up for crystallization using a mosquito® crystallization robot (TTP Labtech, Royston UK). Coarse screens were typically setup onto Greiner 3-well plates using three different drop ratios of precipitant to protein per condition (100+50 nl, 75+75 nl and 50+100 nl). Initial hits were optimized further using Greiner 1-well plates and scaling up the drop sizes in steps. All crystallizations were carried out using the sitting drop vapor diffusion method at 4 °C. BRD4 (1) Crystals were cryo-protected using the well solution supplemented with additional ethylene glycol and were flash frozen in liquid nitrogen. Data were collected at a Rigaku FRE Superbright using an RAXIS-VI detector at 1.52 Å. Indexing and integration was carried out using MOSFLM 2 and scaling was performed with SCALA 3 . Initial phases were calculated by molecular replacement with PHASER 4 using an ensemble of known bromodomain models (PDB IDs 2OSS, 2OUO, 2GRC, 2OO1, 35 3DAI, 3D7C, 3DWY). Initial models were built by ARP/wARP 5 and building was completed manually with COOT 6 . Refinement was carried out in REFMAC5 7 . Thermal motions were analyzed using TLSMD 8 and hydrogen atoms were included in late refinement cycles.
Data collection and refinement statistics can be found in Supplemental 
